Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Xenova Group PLC (XNVA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Msgs
Recent Events
Aug 13Price hit new 52-week low ($5.16)
Location
240 Bath Road, Slough
Berkshire SL1 4EF, UK
Phone: (212) 696-4455
Fax: (212) 696-9180
Email: webmaster@xenova.co.uk
Employees (last reported count): 59
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 18%
·Institutional: 0% (0% of float)
(5 institutions)
·Net Inst. Selling: 1,000  shares (+19.90%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Xenova Group PLC is a biopharmaceutical group based in the United Kingdom focusing on the discovery and development of novel small-molecule drugs, primarily for the treatment of cancer, which have the potential to be administered in oral and intravenous formulations. Xenova currently operates as a single operating unit, Xenova Limited. Xenova Limited undertakes the discovery and development, including the conduct of clinical trials, of the Company's drug candidates. The operating unit is currently undertaking cancer research targeting topoisomerases I and II, multi-drug resistance, PAI-1 and telomerase. It has two drugs in clinical trials: XR9576, designed to overcome P-gp mediated multi-drug resistance in common cancer types as an addition to standard chemotherapy, and XR5000, a drug used in the treatment of a wide range of cancers. The Company also has early-stage research programs targeting MRP in cancer and in asthma, PAI-1 in thrombosis targets and the inhibition of telomerase.
More from Market Guide: Expanded Business Description

Financial Summary
Xenova is a biopharmaceutical company focused on the discovery and development of novel small-molecule drugs, primarily for the treatment of cancer. For the three months ended 3/31/01, revenues totalled L0, down from L78K. Net loss before U.S. GAAP rose 23% to L2.2 million. Revenues reflect the absence of software license sales. Higher loss reflects increased research and development expenditures, and the inclusion of a loss on the sale of a business.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 501; after tax earnings were -4,308. (Preliminary; reported in thousands of British Pounds.)

More from Market Guide: Significant Developments

Officers
John B.H. Jackson, Chmn.
David A. Oxlade, CEO
Daniel Abrams, CFO/Secy.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- XNVAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 13-Aug-2001
$5.16 
Recent Price$6.37 
52-Week High
on 6-Sep-2000
$21.56 
Beta0.02 
Daily Volume (3-month avg)8,000 
Daily Volume (10-day avg)2,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-67.1%
52-Week Change
relative to S&P500
-55.9%
Share-Related Items
Market Capitalization$44.1M
Shares Outstanding6.92M
Float5.68M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 10 on 10-July-2001
Per-Share Data
Book Value (mrq*)$2.04 
Earnings (ttm)-$2.14 
Earnings (mrq)-$0.44 
Sales (ttm)$0.08 
Cash (mrq*)$1.70 
Valuation Ratios
Price/Book (mrq*)3.12 
Price/EarningsN/A 
Price/Sales (ttm)75.42 
Income Statements
Sales (ttm)$729.0K
EBITDA (ttm*)-$14.3M
Income available to common (ttm)-$17.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-91.51%
Return on Equity (ttm)-108.24%
Financial Strength
Current Ratio (mrq*)5.74 
Debt/Equity (mrq*)0 
Total Cash (mrq)$22.0M
Short Interest
As of 8-Aug-2001
Shares Short6,000 
Percent of Float0.1%
Shares Short
(Prior Month)
1,000 
Short Ratio0.75 
Daily Volume8,000 
ADR Information
Shares/ADR10
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001);   dollar amounts based on an exchange rate of 1.45 Dollars/British Pounds

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.